A Randomized, Double-blind Clinical Trial to Evaluate Lot-to-lot Consistency , Immunogenicity and Safety of Quadrivalent Influenza Vaccine (Split Virion), Inactivated in Health Populations Aged 9~59 Years Old
Latest Information Update: 19 Sep 2023
At a glance
- Drugs Influenza-virus-vaccine-quadrivalent-Sinovac-Biotech (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Sinovac Biotech
Most Recent Events
- 15 Sep 2023 Status changed from recruiting to completed.
- 11 Jan 2023 Planned End Date changed from 30 Apr 2023 to 30 Dec 2023.
- 11 Jan 2023 Planned primary completion date changed from 30 Oct 2022 to 30 Dec 2023.